Navigation Links
ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials
Date:8/27/2007

PARIS, August 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announced that its drug discovery collaboration with Allergan Inc. (NYSE: AGN), a global speciality pharmaceutical and medical device company, has reached a success milestone. As a result of the efforts of the Allergan and ExonHit research team, human clinical testing will be initiated on the first collaboration New Chemical Entity (NCE). This NCE (designated EHT/AGN001) has a novel mechanism of action and will enter a phase I study later this year.

The objectives of Allergan and ExonHit's strategic collaboration are to identify, develop and commercialise drugs targeted at the treatment of neurodegenerative diseases, pain and ophthalmology. The collaboration was initiated in 2003 and has been extended twice as a consequence of its good productivity.

"We are happy to see that this collaboration has lead to a clinical candidate in such a short period of time. This success is a result of the dedicated efforts and focus by the research teams from both companies," said Dr. Scott Whitcup, Executive Vice President, Research & Development of Allergan Inc.

"By industry standards, this collaboration's productivity is exceptional, delivering a clinical product in less than four years together with two other innovative pre-clinical projects," stated Bruno Tocque President of the Management Board of ExonHit. He added "I would like to express my gratitude to our scientists who have developed a drug discovery engine enabling this achievement".

Under the terms of the agreement, Allergan will assume responsibility for the ongoing clinical development and commercialisation of EHT/AGN001. Contingent upon
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences ® , a leading ... precision medicine, today announced the presentation of data ... of Caris Molecular Intelligence ® , the company,s ... identify targeted treatment options for patients with rare ... results of which are to be presented in ...
(Date:5/29/2015)... RESEARCH TRIANGLE PARK, N.C. , May 29, 2015 ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Jefferies 2015 Global ... The presentation and the immediately following Q&A session ... AM Eastern Time, and can be accessed via a live ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies"  to their offering.  ... remains a challenge in management. With nearly ... the seven major markets of the world ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... LLC, a premier developer of innovative quality control products ... (PET) imaging, is pleased to announce the only ... of Standards and Technology (NIST) for accurate measurement of ... 1 millicurie (37 MBq) strength.  Fluorine-18 is an important ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following ... Monday, February 28, 2011 at 4:30 p.m. ET / 1:30 ... log onto our Web site listed above. If you are ... the webcast will be available for a limited time at ...
... NEW YORK and SAN DIEGO, Feb. 14, 2011 Polaris ... today announced the enrollment of the first patient in a ... of small cell lung cancer (SCLC).  The trial, sponsored by ... Duke University Medical Center and will soon commence at St. ...
Cached Biology Technology:RadQual, LLC Announces a New Industry Leading Dose Calibrator Reference Standard 2Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer 2Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer 3
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... New article postings for Geology cover glacial erosion ... changing the face of Earth; collisional shortening in the ... typhoon Morakot in 2009; a new type of iron ... using fossil marine plankton records in 70-million-year-old sediments as ...
... chemical sensors for your iPhone, and new materials with ... power, and new crime scene investigation techniques this month ... materials, interfaces, and processing. Detailed press releases will follow ... & Exhibition will take place Oct. 27 - Nov. ...
... Michael J. Fox Foundation for Parkinson,s Research and Shake ... project by Sydney,s Garvan Institute of Medical Research to ... Parkinson,s disease. Long non-coding RNAs are complex molecules, ... regulatory roles in the body. Unlike conventional genes, they ...
Cached Biology News:Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 2Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 3Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 4Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 5Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 6Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 7Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 8Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 9AVS science symposium in Long Beach Oct. 27 -- Nov. 2 2Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2
... paraffin tissue array is designed for ... interest in extensive panels of different ... heart, kidney, liver, lung, muscle, spleen ... positively charged glass slide. Each ...
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
in vitro Translation, Accessory Products...
Biology Products: